Qiagen N.V. (QGEN) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 75
- Profitability 75
- Business Quality 65
- Balance Sheet 55
- Cash Flow 80
Why this rating?
Health 71/100 — High Quality
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Qiagen N.V. (QGEN) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Qiagen N.V. 71/100 (High Quality) due to solid business quality, steady revenue growth, and manageable leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Adequate
- Valuation Attractive
Financial highlights
Valuation
- P/E 21.51
- Forward P/E 16.24
- PEG 1.16
- EV/Revenue 4.68
Profitability
- Revenue Growth 0.3%
- Gross Margin 66.4%
- Operating Margin 26.3%
- Net Margin 19.5%
- ROE 11.9%
Financial strength
- Cash $793.50M
- Debt $1.65B
- Net Cash $-860.20M
- Free Cash Flow $447.20M
- Current Ratio 2.85
Similar companies
Peers in Diagnostics & Research, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Veracyte, Inc. Diagnostics & Research VCYT$42.45 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Illumina, Inc. Diagnostics & Research ILMN$211.06 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- CareDx, Inc. Diagnostics & Research CDNA$50.31 73 Health 73 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Danaher Corporation Diagnostics & Research DHR$205.23 68 Health 68 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Quest Diagnostics Incorporated Diagnostics & Research DGX$235.50 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Sotera Health Company Diagnostics & Research SHC$18.59 67 Health 67 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Revvity, Inc. Diagnostics & Research RVTY$127.08 66 Health 66 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BillionToOne, Inc. Diagnostics & Research BLLN$99.06 65 Health 65 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Qiagen N.V. (QGEN).